Posted by Michael Wonder on 02 Aug 2021
GSK receives authorization under Health Canada's Interim Order for sotrovimab for Injection to treat COVID-19 in high-risk adults and adolescents
30 July 2021 - GSK announced today that Health Canada has granted an Interim Order Authorisation for sotrovimab for Injection (sotrovimab, previously VIR-7831) for the treatment of mild to moderate COVID-19, confirmed by direct SARS-COV-2 viral testing, in adults and adolescents (12 years of age and older weighing at least 40 kg) who are at high risk for progressing to hospitalisation and/or death.
The authorisation of sotrovimab, a single-dose monoclonal antibody developed in collaboration with Vir Biotechnology, was granted under Health Canada's Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Health Canada's Interim Order expedites authorisation of medicines used for COVID-19, considering public health need.
